Diabetes is running at record levels worldwide, with half of the people estimated to have it not...

Diabetes is running at record levels worldwide, with half of the people estimated to have it not even diagnosed yet, according to the International Diabetes Federation. Poorer countries are where it's spreading most rapidly, with four out of five diabetics now living in low and middle-income countries. Inevitably, the market for diabetes drugs is exploding along with it - now expected to be around $48B - $53B by 2016.

From other sites
Comments (3)
  • Uncle Pie
    , contributor
    Comments (4322) | Send Message
    Novo Nordisk, the Danish company which is the largest provider of diabetes medicines in the world, has outperformed KO and P the shares of the sugary drink companies which are associated with the causes of diabetes, over the past decade. The ADRs trade on the NYSE under the symbol NVO. Berkshire Hathaway has been piling into KO, but owns no shares of NVO. You have to wonder why.


    Long NVO
    14 Nov 2012, 06:36 PM Reply Like
  • curious-george
    , contributor
    Comments (607) | Send Message
    might that be money...lower risk per unit invested dollar...as you suggest, seems that will change
    SNY will do well too...
    14 Nov 2012, 10:09 PM Reply Like
  • Olicash
    , contributor
    Comment (1) | Send Message
    My comment to Uncle Pie: May be Berkshire Hathaway is strategically already one step ahead by investing in DaVita. Kidney failure as a complication of diabetes is correlated with the epidemic growth of diabetes.


    Long NVO, LLY, Sanofi, Fresenius Medical Care, DVA
    15 Nov 2012, 05:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs